New drug cocktail targets tough lung cancer

NCT ID NCT06249282

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests a combination of two drugs, carfilzomib and sotorasib, in people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation. The study aims to find the safest dose and watch for side effects. About 15 participants who have already tried a KRAS inhibitor will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib and sotorasib
What this could lead to: If it works, this could point toward a new treatment option for people with KRAS G12C lung cancer who have already tried other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 15 people. The main goal is safety, not yet effectiveness. The combination may cause serious side effects or may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG NON-SMALL CELL CARCINOMA METASTATIC LUNG NON-SMALL CELL CARCINOMA STAGE III LUNG CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
City of Hope at Irvine Lennar
RECRUITING

Irvine, California, 92618, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.